Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 3
2013 2
2014 2
2015 2
2016 2
2018 3
2019 1
2020 1
2021 2
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.
Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R, Dickins B, Altmann H, Kramer M, Knaus HA, Blazar BR, Radojcic V, Zeidner JF, Arruda A, Wang B, Abbas HA, Minden MD, Tasian SK, Bornhäuser M, Gojo I, Luznik L. Rutella S, et al. Among authors: mukhopadhyay r. J Clin Invest. 2022 Nov 1;132(21):e159579. doi: 10.1172/JCI159579. J Clin Invest. 2022. PMID: 36099049 Free PMC article.
Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides.
Wang Y, Mukhopadhyay R, Roy S, Kapoor A, Su YP, Charman SA, Chen G, Wu J, Wang X, Vennerstrom JL, Arav-Boger R. Wang Y, et al. Among authors: mukhopadhyay r. Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01735-18. doi: 10.1128/AAC.01735-18. Print 2019 Jan. Antimicrob Agents Chemother. 2018. PMID: 30373792 Free PMC article.
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
Zeidner JF, Vincent BG, Ivanova A, Moore D, McKinnon KP, Wilkinson AD, Mukhopadhyay R, Mazziotta F, Knaus HA, Foster MC, Coombs CC, Jamieson K, Van Deventer H, Webster JA, Prince GT, DeZern AE, Smith BD, Levis MJ, Montgomery ND, Luznik L, Serody JS, Gojo I. Zeidner JF, et al. Among authors: mukhopadhyay r. Blood Cancer Discov. 2021 Sep 10;2(6):616-629. doi: 10.1158/2643-3230.BCD-21-0070. eCollection 2021 Nov. Blood Cancer Discov. 2021. PMID: 34778801 Free PMC article. Clinical Trial.
A Novel Bioimpedance-Based Detection of Miltefosine Susceptibility Among Clinical Leishmania donovani Isolates of the Indian Subcontinent Exhibiting Resistance to Multiple Drugs.
Ghosh S, Biswas S, Mukherjee S, Pal A, Saxena A, Sundar S, Dujardin JC, Das S, Roy S, Mukhopadhyay R, Mukherjee B. Ghosh S, et al. Among authors: mukhopadhyay r. Front Cell Infect Microbiol. 2021 Nov 29;11:768830. doi: 10.3389/fcimb.2021.768830. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34912730 Free PMC article.
Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus.
Mukhopadhyay R, Roy S, Venkatadri R, Su YP, Ye W, Barnaeva E, Mathews Griner L, Southall N, Hu X, Wang AQ, Xu X, Dulcey AE, Marugan JJ, Ferrer M, Arav-Boger R. Mukhopadhyay R, et al. PLoS Pathog. 2016 Jun 23;12(6):e1005717. doi: 10.1371/journal.ppat.1005717. eCollection 2016 Jun. PLoS Pathog. 2016. PMID: 27336364 Free PMC article.
Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.
Mukherjee B, Mukhopadhyay R, Bannerjee B, Chowdhury S, Mukherjee S, Naskar K, Allam US, Chakravortty D, Sundar S, Dujardin JC, Roy S. Mukherjee B, et al. Among authors: mukhopadhyay r. Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):E575-82. doi: 10.1073/pnas.1213839110. Epub 2013 Jan 22. Proc Natl Acad Sci U S A. 2013. PMID: 23341611 Free PMC article.
20 results